USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SELEXYS PHARMACEUTICALS CORPORATION
Address:
840 RESEARCH PKWY, STE 516
OKLAHOMA CITY, OK
Phone:
N/A
URL:
N/A
EIN:
562367696
DUNS:
145737131
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $6,761,599.00 3
SBIR Phase II $5,666,256.00 2

Award List:

PEGylation of a Glycosulfopeptide Anti-Inflammatory

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$304,843.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Normal recruitment of circulating white blood cells (leukocytes) into tissues is important in inflammation, lymphocyte homing, and immunological responses. The mechanism of recruitment involves receptors termed selectins that recognize their counter receptors on… More

Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$3,342,787.00
Agency:
HHS
Principal Investigator:
Scott A. Rollins
Abstract:
DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step i n the recruitment of white blood cells to… More

Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$3,113,969.00
Agency:
HHS
Principal Investigator:
Scott A. Rollins
Abstract:
DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory dis order of the gastrointestinal tract that… More

Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,553,342.00
Agency:
HHS
Principal Investigator:
Scott A. Rollins – 203-776-1790
Abstract:
DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal… More

Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$3,112,914.00
Agency:
HHS
Principal Investigator:
Scott A. Rollins – 203-776-1790
Abstract:
DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance… More